UPDATE: Zenodo migration postponed to Oct 13 from 06:00-08:00 UTC. Read the announcement.

Preprint Open Access

Early Treatment of the Inflammatory Stage of COVID-19 and its rationale

Bastian, Elizabeth; Karrow, Niel A.; Halgas, Ondrej; Nakatsu, Kanji


  COVID-19 is typically an acute infection caused by SARS-CoV-2 virus that lasts 2-3 weeks. However, in some instances the disease may worsen and lead to Acute Respiratory Distress Syndrome (ARDS) and multisystem damage that can result in long term disability or even death if not treated early and effectively.

  This article focuses on the early inflammatory phase of COVID-19, which typically starts about a week after the onset of first symptoms associated with the initial viral stage. A readily accessible treatment option comprising well-known glucocorticoids, antihistamines, leukotriene antagonists and anticoagulants is included, and its rationale is given. This treatment option is especially relevant for general practitioners and emergency room clinicians and can be initiated prior to the need for hospitalization and in most cases may also prevent it.

Files (311.1 kB)
Name Size
Early Treatment of the Inflammatory Stage of COVID-19 and its rationale.pdf
260.3 kB Download
Supplement - dr_chetty_8th_day_therapy.pdf
50.8 kB Download
All versions This version
Views 23,97323,973
Downloads 32,34132,341
Data volume 5.6 GB5.6 GB
Unique views 21,64121,641
Unique downloads 25,07825,078


Cite as